Use of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumour (NET) patients in Germany – A retrospective evaluation in German centers for NET

Use of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumour (NET) patients in Germany – A retrospective evaluation in German centers for NET - LUNET-2

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031054

Enrollment

100

Registered

2023-01-18

Start date

2022-12-21

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Confirmed diagnosis of GEP-NET (any localization of the primary tumour including CUP , any Grade)

Interventions

Group 1: chart review (retrospective)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Confirmed diagnosis of GEP-NET (any localization of the primary tumour including CUP2, any Grade) First cycle of primary PRRT of home-brew 177Lu-DOTATATE/DOTATOC or Lutathera® between 01st July 2020 and 30th June 2021

Exclusion criteria

Exclusion criteria: Combination of PRRT with chemotherapy Combination of PRRT with a radionuclide other than lutetium-177 (e.g., yttrium-90).

Design outcomes

Primary

Measure	Time frame
Due to the non-interventional nature of this study, the definition of endpoints as primary or secondary is omitted formally. The following clinical endpoints will be assessed descriptively: Exploratory effectiveness endpoints •Overall survival (OS) •Progression free survival (PFS) •Time to tumour progression (TTP) •Objective response rate (ORR) •Time to next treatment (TTNT)	—

Countries

Germany

Contacts

Public ContactSteffen Lütte

CSG Clinische Studiengesellschaft mbH

steffen.luette@csg-germany.com+49 30 23080928

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026